Cart
sales@molnova.com
KCL-286
CAS No. 1952276-71-9
KCL-286( —— )
Catalog No. M37200 CAS No. 1952276-71-9
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 131 | In Stock |
|
| 10MG | 212 | In Stock |
|
| 25MG | 445 | In Stock |
|
| 50MG | 697 | In Stock |
|
| 100MG | 939 | In Stock |
|
| 200MG | 1265 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKCL-286
-
NoteResearch use only, not for human use.
-
Brief DescriptionKCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
-
DescriptionAnticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorRetinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1952276-71-9
-
Formula Weight334.33
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)C=1C=CC(=CC1)C2=NOC(=N2)C=3OC=4C(C3)=C(C=CC4C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..?
molnova catalog
related products
-
BMS493
BMS493 is an inverse agonist of the pan-retinoic acid receptor (RAR) that inhibits retinoic acid-induced differentiation, enhances the interaction of nuclear co-inhibitors with RARs, attenuates RA signaling, potentiates TPP-induced toxicity, and inhibits the increase in phospholipase A2 activity.
-
Bexarotene
Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.
-
BX-517
BX-517 is a potent and selective inhibitor of PDK1.
